OncoMatch/Clinical Trials/NCT07318558
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Is NCT07318558 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Sacituzumab tirumotecan and Bevacizumab for ovarian neoplasms.
Treatment: Sacituzumab tirumotecan · Bevacizumab · Rescue Medications — Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol.
Must have received: debulking surgery — primary or interval
Has completed primary debulking surgery or interval debulking surgery.
Cannot have received: systemic anticancer therapy
Exception: first-line platinum-based chemotherapy required by inclusion criteria
Received prior systemic anticancer therapy, with the exception of the first-line platinum-based chemotherapy required by the inclusion criteria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mount Sinai Cancer Center ( Site 0029) · Miami Beach, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07318558 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages